CompletedNot Applicable

Multi-Detector CT Angiography With 3D Reconstruction Versus Digital Subtraction Angiography

Egypt70 participantsStarted 2022-05-01

Plain-language summary

This study aims to investigate the feasibility and accuracy of Multi-Detector CT angiography acquired before Trans-arterial Chemo-embolization (TACE) in detecting Hepato-cellular carcinoma feeding vessels compared to DSA angiography acquired during TACE.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with HCC not suitable for resection, liver transplantation, or percutaneous ablation. * CHILD class A/B cirrhosis. * patent main portal vein. * less than 50% involvement of the liver by the tumor. * no vascular invasion or extrahepatic spread of the HCC. * normal renal functions. * bilirubin level \< 2 mg/dl . Exclusion Criteria: * Pre-TACE Multi-Detector CT raw DICOM images could not be obtained for 3D processing * patients with only available Pre-TACE MRI images * Failed TACE due to technical factors * Non-selective TACE technique

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

feeding vessels detectability

Timeframe: Baseline

Trial details

NCT IDNCT05304572

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05-01

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.